One year on from the first approved TIL Therapy in the US, and with Canada and EMA expected to make approval decisions in the coming months, this is a pivotal time for drug developers looking to address treatment-resistant solid tumors. 

Returning for its 7th year, the TIL Therapies Summit remained the go-to forum for this close-knit community, created with the mission to transform end-to-end TIL development and deliver best-in-class therapies to treat solid tumor indications with significant unmet needs. 

With more patients being treated than ever, this summit united a global collective of biopharma, academic thought leaders, clinicians, and patients as they shared their cutting-edge research into engineered TIL, easier manufacturing, and lived experiences with TIL Therapies.